TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03173625

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AC-076 for s.c. administration
Description: Lyophilized AC-076A to be reconstituted with 1 mL of water for injection

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Sterile 0.9% w/v sodium chloride solution
Study: NCT03192189

Intervention type: OTHER
Intervention: monitoring for progression to chronic kidney disease
Description: Collect clinical information and assess risk factors
Study: NCT02675322

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Danlou Tablets
Description: Danlou tablets were approved by China Food and Drug Administration for the treatment of ischemic heart disease in 2005 (Z20050244).

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo with no chemical effects.
Study: NCT00142246

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intermittent preventive treatment (SP and amodiaquine)
Description: Oral medication. SP: single dose given over one day; amodiaquine: 3 daily doses over 3 days. Dosage has given according to age.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Three doses given over three days (Day 1: placebo SP + placebo AQ; Days 2 and 3: placebo AQ). Dosage given according to age
Study: NCT00540111

Intervention type: DIETARY_SUPPLEMENT
Group type: OTHER
Intervention: soluble fiber® (partially hydrolyzed guar gum)
Description: HIV-positive individuals with hypertriglyceridemia and who had been on the same HAART regimen for at least 6 months, had no change in therapy during the study,received 20g/day of soluble fiber for 4 months at pre-established times.
Study: NCT00365885

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Computer-based clinical decision support.
Description: computer decision support system that generates notifications about sentinel health events and communicates this information via electronic mail to care managers, feedback reports to clinical managers, and letters to patients

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Computer-based clinical decision support.
Description: computer decision support system that generates notifications about sentinel health events and communicates this information via electronic mail to care managers, feedback reports to clinical managers, and letters to patients

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Computer-based clinical decision support.
Description: computer decision support system that generates notifications about sentinel health events and communicates this information via electronic mail to care managers, feedback reports to clinical managers, and letters to patients
Study: NCT01597856

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: SBIRT
Description: SBIRT Therapy overview-~1. Therapist explains purpose of the therapy.~2. Inquiry about Compensation examination-ask if Veteran has questions about determination process and address concerns.~3. Discuss relationship between PTSD and substance use- long-term substance use is a form of avoidance and barrier to recovery.~4. Discuss treatment needs, administer screening, provide feedback.
Study: NCT03470805

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Olaparib
Description: Olaparib will be dispensed to patients on Day 1 and every 28 days thereafter until disease progression, unacceptable toxicity, withdraws from the study or closure of the study
Study: NCT04197791

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Neuromuscular Electrical Stimulation
Description: Neuromuscular Electrical Stimulation(NMES) to core stabilization muscles will be applied using 8 electrodes. The application time will be 30 minutes. Treatment will be programmed for 2 days per week. The program will continue for 6 weeks.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Core Stabilization Exercises
Description: Warm-up and cool-down exercises will be performed before and after core stabilization exercises. The exercise time will be 30 minutes. Treatment will be programmed for 2 days per week. The program will continue for 6 weeks.
Study: NCT01316913

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK573719/GW642444 125/25
Description: 125/25 mcg once-daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK573719/GW642444 62.5/25
Description: 62.5/25 mcg once-daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK573719
Description: 125 mcg once-daily

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: tiotropium bromide
Description: 18 mcg once-daily
Study: NCT00884026

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: AIx measurement with a Sphygmacor TM
Description: All subjects will have their AIx measured prior to surgery. After 30 subjects are recruited, they will be split into 2 groups. Group 1 will be those subjects who developed hypotension, and Group 2 will be those subjects who did not develop hypotension. We will then look at the preoperative measured AIx to determine whether there is a baseline difference between the two groups. A threshold value of the AIx with the best sensitivity and specificity for prediction of hypotension will then be determined.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: AIx measurement with a Sphygmacor TM
Description: The second part of the study will then use the threshold AIx value found from the subjects who developed hypotension from the first 30 subjects to prospectively predict hypotension after spinal anesthesia in another 60 subjects
Study: NCT02615132

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: iPad
Description: Using iPad speech therapy apps on patients with post-stroke communication deficits
Study: NCT00559468

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Propofol
Description: Propofol IV administered for induction and maintenance of anesthesia, based on randomization.
Study: NCT03697603

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Brexpiprazole
Description: Tablets, Oral, once daily, 14 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Brexpiprazole
Description: Tablets, Oral, once daily, 14 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Tablets, Oral, once daily, 14 weeks
Study: NCT00291694

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: celecoxib
Description: Celecoxib 400 mg BID

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: placebo
Study: NCT02733159

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pembrolizumab
Description: anti PD-1
Study: NCT02115750

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Etanercept
Description: Head-to-head comparison

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CHS-0214
Study: NCT02818348

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: darunavir/cobicistat
Description: 800/150 mg, once daily during 35 days + etravirine 400 mg, once daily during 14 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: darunavir/cobicistat
Description: 800/150 mg, once daily during 35 days + etravirine 400 mg, once daily during 14 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: etravirine
Description: 400 mg, once daily during 28 days + darunavir/cobicistat 800/150 mg, once daily during 7 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: etravirine
Description: 400 mg, once daily during 28 days + darunavir/cobicistat 800/150 mg, once daily during 7 days
Study: NCT02816398

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Percutaneous creation of an arteriovenous fistula
Description: Use of catheter system for percutaneous creation of an arteriovenous fistula
Study: NCT02958566

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Acetaminophen

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gabapentin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Orphenadrine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lidocaine
Study: NCT02218073

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-42756493 10 mg tablet
Description: Participants will be administered with 10 milligram (mg) JNJ-42756493 tablet orally either on Day 1 of Period 1 or on Day 1 of Period 2.
Study: NCT02958566

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Marcaine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketamine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methadone

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tramadol
Study: NCT04876443

Intervention type: DIAGNOSTIC_TEST
Intervention: Study questionnaire
Description: Study questionnaire related to drinking behaviour
Study: NCT05217329

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: smart phone App rehabilitation
Description: stroke subjects use smart phone to complete therapeutic tasks 5 min/session total 8 sessions/day with affected arm or bilateral arm movement for 6 weeks

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: conventional rehabilitation
Description: stroke subjects receive conventional rehabilitation home program for 6 weeks(30min/day)
Study: NCT03892109

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: No Cord impression material
Description: the no cord self- retracting impression material placed directly in the tray

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: No Cord impression material
Description: the no cord self- retracting impression material placed directly in the tray

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: No Cord impression material
Description: the no cord self- retracting impression material placed directly in the tray
Study: NCT02958566

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketorolac
Study: NCT03892109

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: No Cord impression material
Description: the no cord self- retracting impression material placed directly in the tray

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: cord
Description: Cords were placed in the gingival sulcus with use of a cord packer, and left in situ for 10 min before making the impression. None of the retraction cords were immersed in any solution or medicaments prior to insertion.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: cord
Description: Cords were placed in the gingival sulcus with use of a cord packer, and left in situ for 10 min before making the impression. None of the retraction cords were immersed in any solution or medicaments prior to insertion.

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: cord
Description: Cords were placed in the gingival sulcus with use of a cord packer, and left in situ for 10 min before making the impression. None of the retraction cords were immersed in any solution or medicaments prior to insertion.
Study: NCT02958566

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Morphine Sulfate

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fentanyl

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dilaudid
Study: NCT02958566

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hydrocodone-Acetaminophen Tab 5-325 MG

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Morphine Sulfate
Description: PCA

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fentanyl
Description: PCA

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dilaudid
Description: PCA

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: HYDROCODONE/ACETAMINOPHEN 5 Mg-325 Mg ORAL TABLET
Description: Breakthrough
Study: NCT00853606

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: avanafil
Description: All subjects will initially be assigned to treatment with avanafil 100 mg. Subjects who are unable to tolerate treatment with 100 mg may undergo dose reduction to 50 mg. Subjects who tolerate avanafil 100 mg but who desire increased efficacy may request a dose increase to 200 mg.
Study: NCT01827761

Intervention type: BEHAVIORAL
Intervention: Questionnaire
Description: After informed consent for this study is obtained, patients will be given questionnaire #1 that includes rating their knowledge of the side effects of treatment, their understanding of the treatment schedule, what do in the event of complication, how to reach the medical team and an assessment of the level of anxiety. The questionnaire will be repeated at day 1 of the first chemotherapy treatment to assess the effectiveness of the teaching session. In addition, questionnaire #3 will be administered at day 1 of cycle 2 of their first chemotherapy.
Study: NCT01341769

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Dietary Intervention

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Dietary Intervention

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Dietary Intervention

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Dietary Intervention
Study: NCT02110381

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Device guided breathing RESPeRATE
Description: Participants will use a device called RESPeRATE which will measure how many breaths they take per minute. A strap wraps around the participants chest that measures breathing frequency. Headphones plug into the device to inform participants about their breathing. The device will help guide participants to breathe slowly using musical tones, with a goal of about ten breaths per minute.~Participants will use the breathing device 5 days per week for about 15 minutes each day. Participants will keep a log of their exercises and return it with each visit.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Device guided breathing RESPeRATE
Description: Participants will use a device called RESPeRATE which will measure how many breaths they take per minute. A strap wraps around the participants chest that measures breathing frequency. Headphones plug into the device to inform participants about their breathing. The device will help guide participants to breathe slowly using musical tones, with a goal of about ten breaths per minute.~Participants will use the breathing device 5 days per week for about 15 minutes each day. Participants will keep a log of their exercises and return it with each visit.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Isometric hand grip Zona Plus
Description: Participants will use a device called the Zona Plus, which they will hold in their hand and squeeze. A session consists of 2 minutes of squeezing the device followed by 1 minute of rest. Participants will do a total of 4 sessions (2 sessions for each hand) for a total of about 12 minutes of exercise.~Participants will do these exercises 5 days per week. Participants will keep a log of their exercise and return it with each visit.
Study: NCT02218073

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-42756493 10 mg Oral Solution
Description: Participants will be administered with 10 mg JNJ-42756493 oral solution either on Day 1 of Period 1 or on Day 1 of Period 2.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-42756493 10 mg Oral Solution
Description: Participants will be administered with 10 mg JNJ-42756493 oral solution either on Day 1 of Period 1 or on Day 1 of Period 2.
Study: NCT02110381

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Isometric hand grip Zona Plus
Description: Participants will use a device called the Zona Plus, which they will hold in their hand and squeeze. A session consists of 2 minutes of squeezing the device followed by 1 minute of rest. Participants will do a total of 4 sessions (2 sessions for each hand) for a total of about 12 minutes of exercise.~Participants will do these exercises 5 days per week. Participants will keep a log of their exercise and return it with each visit.
Study: NCT03065400

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: 200 mg of Pembolizumab administered via intravenous infusion over 30 mins given every 3 weeks
Study: NCT01683188

Intervention type: DRUG
Group type: OTHER
Intervention: vemurafenib + HD IL-2

Intervention type: DRUG
Group type: OTHER
Intervention: vemurafenib + HD IL-2
Study: NCT01915888

Intervention type: OTHER
Intervention: Data interpretation
Description: The data collected for each group will be fully de-identified, interpreted and analysed separately for the 2 databases (MarketScan Commercial and MarketScan Medicaid).

Intervention type: OTHER
Intervention: Data interpretation
Description: The data collected for each group will be fully de-identified, interpreted and analysed separately for the 2 databases (MarketScan Commercial and MarketScan Medicaid).

Intervention type: OTHER
Intervention: Data interpretation
Description: The data collected for each group will be fully de-identified, interpreted and analysed separately for the 2 databases (MarketScan Commercial and MarketScan Medicaid).

Intervention type: OTHER
Intervention: Data interpretation
Description: The data collected for each group will be fully de-identified, interpreted and analysed separately for the 2 databases (MarketScan Commercial and MarketScan Medicaid).
Study: NCT04103099

Intervention type: DIETARY_SUPPLEMENT
Group type: OTHER
Intervention: HLNatural Immune
Description: Vitamin C, Echinacea, Ivy Extract, Zinc, Ginger and Turmeric in a powder form mixed with water
Study: NCT02252822

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Overcoming Bulimia Online Programme
Study: NCT04365205

Intervention type: PROCEDURE
Intervention: Endobronchial biopsy
Description: Endobronchial biopsies will be collected following a standardized procedure based on established guidelines. Before the procedure, asthmatic subjects will receive 400 μg of salbutamol with the aid of an aerosol chamber to open up the airways before the procedure. Anesthesia of the upper airways will be achieved with lidocaine 5% spray. The total amount of lidocaine per subject is limited to 225 mg. General anesthesia will be obtained using propofol (average dose of 1.5 to 2 mg/kg). The fiberoptic bronchoscope (Pentax BF 15V, Argenteuil, France) is introduced and 8 to 10 biopsies will be taken from the middle lobe and the lower right lobe. Standard procedures such as bronchial brushing and bronchial fluid aspiration will also be performed. The duration of bronchoscopy is 15 minutes to 30 minutes. After the procedures, subjects will receive a short acting bronchodilator if required.

Intervention type: PROCEDURE
Intervention: Endobronchial biopsy
Description: Endobronchial biopsies will be collected following a standardized procedure based on established guidelines. Before the procedure, asthmatic subjects will receive 400 μg of salbutamol with the aid of an aerosol chamber to open up the airways before the procedure. Anesthesia of the upper airways will be achieved with lidocaine 5% spray. The total amount of lidocaine per subject is limited to 225 mg. General anesthesia will be obtained using propofol (average dose of 1.5 to 2 mg/kg). The fiberoptic bronchoscope (Pentax BF 15V, Argenteuil, France) is introduced and 8 to 10 biopsies will be taken from the middle lobe and the lower right lobe. Standard procedures such as bronchial brushing and bronchial fluid aspiration will also be performed. The duration of bronchoscopy is 15 minutes to 30 minutes. After the procedures, subjects will receive a short acting bronchodilator if required.

Intervention type: PROCEDURE
Intervention: Endobronchial biopsy
Description: Endobronchial biopsies will be collected following a standardized procedure based on established guidelines. Before the procedure, asthmatic subjects will receive 400 μg of salbutamol with the aid of an aerosol chamber to open up the airways before the procedure. Anesthesia of the upper airways will be achieved with lidocaine 5% spray. The total amount of lidocaine per subject is limited to 225 mg. General anesthesia will be obtained using propofol (average dose of 1.5 to 2 mg/kg). The fiberoptic bronchoscope (Pentax BF 15V, Argenteuil, France) is introduced and 8 to 10 biopsies will be taken from the middle lobe and the lower right lobe. Standard procedures such as bronchial brushing and bronchial fluid aspiration will also be performed. The duration of bronchoscopy is 15 minutes to 30 minutes. After the procedures, subjects will receive a short acting bronchodilator if required.
Study: NCT02218073

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-61818549
Description: Participants will receive 100 mcg of JNJ-61818549 as intravenous injection on Day 1 of Period 2 or Day 1 of Period 1.
Study: NCT00968903

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Methylprednisolone
Description: Methylprednisolone 125 mg iv pre-operatively

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Methylprednisolone
Description: Methylprednisolone 125 mg iv pre-operatively
Study: NCT04806841

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Motivational intervention
Description: Three group meeting of 60 minutes to help create effective goals and methods on maintaining motivation to exercise regularly. These meetings will help participants create effective goals and methods on maintaining their motivation to exercise regularly. They will then receive a monthly phone call follow-up at months 4-6.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Control intervention
Description: Participants in the control group will be simply encouraged to exercise at the EPIC center and complete the online surveys. Participants in the control group will receive the skills/tactics at the end of the study.
Study: NCT01706666

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bortezomib
Description: Given SC

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bortezomib
Description: Given SC

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bortezomib
Description: Given SC
Study: NCT01394224

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Levetiracetam
Description: Strength: 100 mg/mL Form: Concentrate for solution for infusion Frequency: Single dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Levetiracetam
Description: Levetiracetam tablets Strength: 500 mg Form: Tablet Frequency: Single dose
Study: NCT00096499

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ispinesib
Description: Given IV
Study: NCT01706666

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cyclophosphamide
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: lenalidomide
Description: Given PO

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dexamethasone
Description: Given PO

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: quality-of-life assessment
Description: Ancillary studies

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: quality-of-life assessment
Description: Ancillary studies

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: quality-of-life assessment
Description: Ancillary studies